Autonomously deploying, CO-evolving sars-COV-2 antiviral: a new paradigm for pandemic prevention
Ended Project Grant Awarded Last action
- Award ID
- R01AI169443
- Recipient
-
Vxbiosciences, Inc. UEI WY7EALRMMHL7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,126,504
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date
- Funding
-
- $8,306,010.19 Federal
- $2,820,494.00 Non-federal
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Sars-COV-2, like all viruses, mutates and transmits; current medical countermeasures do not. This fundamental mismatch between dynamic viruses and our state-of-the-art static interventions means that vaccines and antiviral therapies often require frequent RE-design and RE-development, necessitating repeated (sometimes annual) resolutions to manufacturing and deployment challenges. Without fundamentally different forms of intervention to overcome this mismatch, future pandemics could rival or eclipse the catastrophic loss-of-life and economic impacts of sars-COV-2. To surmount the barriers thwarting current interventions, this proposal will engineer therapeutic molecular parasites of sars-COV-2 that can CO-adapt and transmit among infected hosts. The key innovations of this approach are that these therapeutic parasites: (i) establish CO-evolutionary arms races, CO- evolving with wild-type virus to overcome resistance, (II) replicate and self-renew, acting as single-administration therapies that circumvent compliance issues, and (III) spread via the exact same risk factors and transmission routes as sars-COV-2-autonomously utilizing superspreaders to deploy the intervention-thereby circumventing manufacturing-at-scale and roll-out challenges. By design, these 'piggybacking' molecular parasites cannot replicate in uninfected hosts. Epidemiological models indicate that such molecular-parasite therapies would surmount the universal barriers to pandemic control and lower prevalence for many viruses below levels achievable by vaccination or antiviral therapy campaigns. The molecular rationale for developing molecular-parasite antivirals rests on ablating essential protein-encoding elements (i.e., trans-acting factors) to create conditionally replicating vectors that produce therapeutic interfering particles (tips) when complemented in trans by wild-type virus superinfection. The crucial difference between tips and classical defective viral particles is that tips are engineered to have an R0 > 1-they efficiently mobilize, and transmit. As deletion variants, tips act as parasites, replicating only in virus-infected cells by stealing critical replication and packaging elements from the wild-type virus. By starving the wild-type pathogen of these critical elements, tips reduce wild-type pathogen levels. Critical feasibility precedents include that tips have been engineered to inhibit other viruses in vivo. Regulatory and ethical precedents include initial FDA clearances for HIV tip phase-i clinical trials supported by the NIH and DOD. This proposal will screen randomized synthetic libraries of sars-COV-2 variants to identify tip candidates, test tip efficacy and transmissibility in animal models, devise and test delivery and dosage formulations, and test tolerability, safety, and immunogenicity in a phase-i clinical trial. The deliverable of this project will be the creation of a novel paradigm to counter sars-COV-2 and emerging pandemics by development and DE-risking of an intervention that overcomes the universal barriers to infectious disease control.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$1,329,156 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,997,089 | $0 | |
| Amendment | $1,997,089 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $2,820,494 | $0 | |
| Original award | $2,820,494 | $2,820,494 |
Quick answers
Who received award R01AI169443?
R01AI169443 was awarded to Vxbiosciences, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 24, 2021.
How much is award R01AI169443 worth?
$11,126,504 has been obligated on R01AI169443: $8,306,010 in federal funding and $2,820,494 in non-federal funding.
Which agency awarded R01AI169443?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded R01AI169443, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award